Introduction 45 46
In the modern drug discovery and development process, high-throughput screens (HTS) 47 of drugs have become a common and important step in the identification of novel treatments for 48 disease. In the past decade, studies describing or citing high throughput drug screening are 49 increasingly prevalent, topping 1000 per year for the past 5 years (Figure 1 ) and span many 50 disease domains such as cancer, neurodegenerative disease, and cardiopulmonary diseases. 51
These screens are often phenotypic in nature whereby a large panel of compounds of known, 52 presumed known, and/or unknown mechanisms of action are tested in a biological model of 53
interest and generate phenotypic readouts such as apoptosis or proliferation. While these types 54 of screens facilitate the rapid identification of biologically active drugs or chemical probes, they 55 also present several challenges. 56 57
Figure 1 -High throughput drug screening is an increasingly common experimental 58 approach. Yearly count of Pubmed-indexed publications that appear with the search term "high 59 throughput drug screening." Search performed on January 30, 2018. 60 61
One prevailing challenge is the identification of the specific biological mechanisms within 62 a cell that determine the response in a screen. The search for novel drugs constantly pushes 63 the pharmaceutical researchers to include novel chemical sets in phenotypic screens, with the 64 caveat that the underlying mechanism of action (MoA) of a particular compound cannot usually 65 be gleaned from the phenotypic screens.
(1) Most of the time, identifying the MoA requires 66 additional experimentation, particularly if the molecule represents a novel or understudied 67 chemical entity. Another challenge is that the polypharmacologic nature of many small 68 molecules can make it difficult to interpret HTS results as a given drug may affect multiple 69 targets with a range of efficacy. This, in turn, presents the difficulty of consolidating multiple 70 targets into a unified biological mechanism or set of mechanisms leading to poorly annotated 71 targets, misunderstood MoAs (2), and unknown or ambiguous off-targets with potential deadly 72 side effects (3, 4) . A final challenge is that identification of related molecules and their targets is 73 not always straightforward; in the context of HTS analysis, structurally and functionally related 74 molecules that are not contained in a screening library might be useful to explore. 75
Multiple tools and databases have attempted to address various aspects of the 76 challenges outlined above (see Table 1 ). These tools allow the user to explore known 77 polypharmacology of small molecules. Many also allow users to explore compound-target 78 relationships by querying either by molecule or by target: DGIdb, DT-Web, BindingDB, 79
Polypharmacology Browser, STITCH, and SuperTarget allow users to identify MoAs/targets of a 80
given compound by evaluating a query drug (5-10), while DT-Web, BindingDB, 81
Polypharmacology Browser, and STITCH allow users to search by chemical similarity using any 82 query molecule (Table 1) . Probe Miner, alternatively, is designed primarily to handle target-83 based queries (11). All tools listed in Table 1 allow users to identify molecules with known 84
polypharmacology, but only two, STITCH and SuperTarget, provide the ability to summarize 85 these targets into biological pathways/mechanisms using a gene list enrichment approach 86 (9, 10) . The final challenge -identifying structurally or functionally related molecules -is 87 addressed by BindingDB, Polypharmacology Browser, . 88
While several of the tools listed address one or more of these challenges, there are 89 some gaps (Table 1) To address these gaps, we developed the Drug-Target Explorer. Specifically, the Drug-106
Target Explorer enables the user to (1) look up targets for individual molecules and groups of 107 molecules, (2) explore networks of targets and drugs, (3) perform gene list enrichment of targets 108
to assess target pathways of compounds, (4) compare query molecules to cancer cell line 109 screening datasets, and (5) discover bioactive molecules using a query target and exploration of 110 these networks. We anticipate that the users will include biologists and chemists involved in 111 drug discovery who are interested in performing hypothesis generation of human targets for 112 novel molecules, identifying off-targets for bioactive small molecules of interest, and exploring of 113 the polypharmacologic nature of small molecules. 114 115 116 Identifying potential off-target effects of novel molecules 131 132
To highlight the use of this app to find potential off-targets of a novel molecule, we 133 queried the Drug-Target Explorer for C21, a recently-published Polo like kinase (PLK) inhibitor 134 that is not captured in our database (13). This molecule inhibits Plk2 and Plk1 in the low nM 135 range, and Plk3 in the low uM range (13). Using a Tanimoto similarity of 0.65 or greater, we 136 identified 14 molecules (Figure 2A , Supplemental Table 1) Table 2 ). These targets must all be considered when evaluating 167 imatinib in human model systems.
168
A more recent example is the tool compound G-5555, a selective PAK1 inhibitor (16). 169 This compound has been used to demonstrate the role of PAK1 in cellular processes such as 170
invasion (17). A search of the Drug-Target Explorer database showed that this molecule not 171 only binds PAK1 (mean pChEMBL = 8.01), but there is qualitative evidence for effects on 172 PAK2/3, and quantitative evidence suggesting an effect on SIK2, MAP4K5, and PAK2 at similar 173 concentrations of G-5555 (mean pChEMBLs 8.05, 8, and 7.96 respectively, Table 2 ). G-5555 174 also may have an effect on STK family proteins (STK3, STK24, STK25, STK26) and LCK. 175
Therefore, any findings with G-5555 with regards to PAK1 inhibition must be validated with other 176 selective inhibitors or genetic approaches, as Jeannott and colleagues did (using other PAK 177 inhibitors such as FRAX597 and FRAX1036, as well as PAK1 silencing RNA), to confirm that 178 the effects observed are PAK1 specific (17). 179 180 181 In order to provide biological context, this app allows the user to aggregate multiple 187 targets from compounds into functional categories. Using the previous example of G-5555, we 188 performed enrichment analysis on the list of targets to identify potential biological pathways and 189
MoAs that this molecule may disrupt. In doing so, we observed that G-5555 targets are enriched 190
in several Gene Ontology terms and KEGG Pathways like T-cell receptor signaling, Ras/MAPK 191 signaling, and Golgi-localized proteins (Supplemental Table 3 ). The app also allows the user to 192 compare the query molecule to drugs in the Cancer Cell Line/CTRP and GDSC/Sanger cell line 193 screening datasets. Specifically, the app identifies the most similar molecule available in these 194 context of follow-up and validation studies, it may be beneficial to use alternate molecules that 206 target LIMK1/2 at the same or greater potency than BMS-5. We used the Drug-Target Explorer 207
to find molecules that target LIMK1 and LIMK2 (Supplemental Table 4 , Figure 2B ). For example, 208 BMS-5 (CHEMBL2141887 in the Drug-Target Explorer) has mean pChEMBLs of 7.33 and 7.07 209 for LIMK1 and LIMK2 respectively. A good alternative to validate the effects of this molecule 210 might be CHEMBL3623442, a relatively structurally distinct small molecule (extended fingerprint 211
Tanimoto similarity of 0.433 to BMS-5 in this database), with pChEMBLs of 9 and 8.52 for 212 LIMK1 and LIMK2 respectively. Another interesting possibility is the identification of multiple 213 molecules with overlapping desired targets and non-overlapping off-targets to reduce off-target 214 effects, or to identify synergistic/additive single-target, multi-drug combinations as outlined by 215 Fitzgerald et al 2006 (19) . Using the above scenario with LIMK1/2, it may be possible to use 216 structurally distinct molecules in combination or in sequence, like CHEMBL3356433 and 217
Compound 31 highlighted in Figure 2B , to reduce off-target effects or inhibit LIMK1/2 in an 218 additive or synergistic manner. The opposite approach could also be taken by finding a single 219 molecule that binds multiple desired targets. In the case of merlin-deficient cells, focal adhesion 220 kinases (FAKs) such as PTK2 (FAK2) and PTK2B, as well as Aurora kinase A (AURKA) have 221 been highlighted as potential targets of interest (18, 20, 21) . Using the Drug-Target Explorer, we 222
can identify molecules that target LIMK1/2, PTK2/2B, and AURKA (Supplemental Table 5 , 223 Figure 2C ). Using this information, a rational hypothesis might be that CYC116 or danusertib 224 could be effective and selective for NF2-deficient tumor cells; to our knowledge, the use of these 225 molecules in this setting has yet not been explored. 226 227 228
Discussion 229 230
In the present study, we demonstrate that the Drug-Target Explorer enables the user to 231 look up targets for novel and known molecules such as C21, G-5555, and imatinib, as well as 232 explore networks of these drugs and their targets. Users can perform target enrichment to 233 consolidate multiple targets to into pathways, compare query molecules to screening datasets, 234
and identify bioactive molecules given a query target. 235
Several future directions are envisioned for this application. The code and database has 236
been designed in such a way that any database with structural information and drug-gene target 237 information (qualitative associations, or quantitative associations that can be coerced to 238 pChEMBL values) can be harmonized and integrated into the database. Therefore, as new 239 datasets become available, such as the recently-published Drug-Target Commons (22), they 240
can be integrated and released. We also envision occasional errors being identified as the 241 database is explored and vetted by users and have included a feedback form for users to 242
suggest new data to integrate, as well as to highlight necessary corrections to the dataset. 243
Currently, the query molecule to full database similarity calculation is computationally intensive. 244
One solution to speed up calculation times may be to implement a locality sensitive hashing 245 method in future versions of the database and web app, such as the method devised by Cao et 246 al 2010 (23) . An additional planned feature for this app is the implementation of a bulk 247 annotation feature to allow users to annotate HTS data with targets and/or putative targets of 248 identical or structurally related molecules. Finally, the integration of a predictive framework for 249 identifying targets of query drugs based on drug and target feature data would enable users to 250 quantitatively predict targets of novel molecular entities rather than manually exploring 251 structurally similar molecules. 252
The Drug-Target Explorer enables users to explore known molecule-human target 253 relationships as they relate to chemical similarity rapidly and with minimal effort. We anticipate 254 that users such as biologists and chemists using chemical probes or studying preclinical 255 therapeutics will find this tool useful in several areas. Specifically, this tool may aid drug 256 discovery efforts by accelerating hypothesis generation, simplifying the transition from 257 phenotypic HTS results to mechanistic studies, and streamlining the identification of candidate 258 molecules that target a protein or mechanism of interest. 259 260
Methods 261 262
To build the database of known compound-target interactions, we aggregated five data 263 sources containing qualitative and quantitative interactions (Figure 3 ). We considered qualitative 264
interactions to be curated compound-target associations with no associated numeric value. 265 Quantitative interactions were defined as compound-target information with a numeric value 266
indicating potency of compound-target binding or functional changes. Qualitative compound-267 target associations were retrieved from the DrugBank 5.0.11 XML database, the DGIdb v3.0.1 268 interactions.tsv file, and ChemicalProbes.org (acc. Jan 17 2018 ChemSpider search (28, 29) . were assigned using the PubChem Chemical Identifier Exchange or manually assigned using 281
ChemSpider and PubChem. Chemical structures were converted to circular fingerprints and the 282 databases were mapped to internal Drug-Target Explorer identifiers. Qualitative and quantitative 283 data were summarized by calculating several summary statistics, and these data were stored 284 together with the internal identifiers to form the Drug-Target Explorer database. 285 286
To consolidate data for "identical" molecules within and across multiple databases, the 287 functional connectivity fingerprint (FCFP6)-like 'circular' fingerprint for each SMILES was 288 calculated using the R interface (rcdk) to the Java Chemical Development Kit (CDK) (30-32). 289
The package was modified to use the latest version of the CDK (2.1.1), which enables 290 perception of chiral centers, enabling differentiation between isomeric molecules. Each unique 291 circular fingerprint and all external IDs and SMILES associated with that fingerprint were then 292 assigned an internal identifier, so that groups of molecules with identical fingerprints were 293 assigned to the same internal ID. The internal molecular IDs were then mapped to each 294 database to permit their aggregation. All datasets were combined and summaries were 295 generated for each compound-target comparison using functions from the R 'tidyverse' (33). 296
The summary metrics described in Table 3 were calculated. One of these metrics, 297
pChEMBL, is used to convey the efficacy of a given molecule. functions and uses, the "Molecules" tab permits molecule-based searching, the "Genes" tab 335 permits target queries, and the "Settings" tab allows the user to pick the fingerprinting method 336 used. 337 338
We developed a Shiny application to permit exploration of the database (34, 35) . For 339 chemical queries, users can search for molecules in the database by one of three methods: 340 from a list of aliases obtained from the source databases, retrieving the chemical structure using 341 the 'webchem' interface to the Chemical Identifier Resolver, or by directly inputting the SMILES 342 string (36). A Tanimoto similarity threshold allows the user to narrow or widen the chemical 343 space of the results. After querying, the input molecule is converted to a fingerprint and it's 344 similarity calculated relative to all molecules in the database, using 'extended' fingerprints. The 345 user then can view the resulting set of molecules as well as the molecule-target relationships in 346 interactive tables and graphs (Figure 4 ). In addition, the user can remove or include molecules 347 on an a-la-carte basis, view the 2D structural representation of the input molecule, and perform 348 target list enrichment analysis (37,38). Furthermore, the query molecule can be compared 349 against molecules in the CTRP and Sanger cancer cell line drug-screening datasets to identify 350 identical or similar structures in these datasets, and compare the relationship between chemical 351 structure and correlations in drug response. 352
For target queries, users can input one or more query HUGO gene(s) and identify 353 molecules that are reported to bind those targets, and view these data in an interactive 
